|
1
|
Guo H, German P, Bai S, Barnes S, Guo W,
Qi X, Lou H, Liang J, Jonasch E, Mills GB, et al: The PI3K/AKT
pathway and renal cell carcinoma. J Genet Genomics. 42:343–353.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Jemal A, Siegel R, Ward E, Murray T, Xu J,
Smigal C and Thun MJ: Cancer statistics, 2006. CA Cancer J Clin.
56:106–130. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Breda A, Lucarelli G, Rodriguez-Faba O,
Guirado L, Facundo C, Bettocchi C, Gesualdo L, Castellano G,
Grandaliano G, Battaglia M, et al: Clinical and pathological
outcomes of renal cell carcinoma (RCC) in native kidneys of
patients with end-stage renal disease: A long-term comparative
retrospective study with RCC diagnosed in the general population.
World J Urol. 33:1–7. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Bangalore N and Bhargava P, Hawkins MJ and
Bhargava P: Sustained response of sarcomatoid renal-cell carcinoma
to MAID chemotherapy: Case report and review of the literature. Ann
Oncol. 12:271–274. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Sun W, Kalen AL, Smith BJ, Cullen JJ and
Oberley LW: Enhancing the antitumor activity of adriamycin and
ionizing radiation. Cancer Res. 69:4294–4300. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Granados-Principal S, Quiles JL,
Ramirez-Tortosa CL, Sanchez-Rovira P and Ramirez-Tortosa MC: New
advances in molecular mechanisms and the prevention of adriamycin
toxicity by antioxidant nutrients. Food Chem Toxicol. 48:1425–1438.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Diaz RR, Kwon JK, Lee JY, Nahm JH, Cho KS,
Ham WS, Cho NH and Choi YD: Renal pelvic urothelial carcinoma with
vena caval thrombus mimicking renal cell carcinoma. Korean J Urol.
55:624–627. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Wu XX, Zeng Y, Jin XH and Kakehi Y:
Enhanced susceptibility of adriamycin-treated human renal cell
carcinoma cells to lysis by peripheral blood lymphocytes and tumor
infiltrating lymphocytes. Oncol Rep. 18:353–359. 2007.PubMed/NCBI
|
|
9
|
Milner LS, Wei SH and Houser MT:
Amelioration of glomerular injury in doxorubicin hydrochloride
nephrosis by dimethylthiourea. J Lab Clin Med. 118:427–434.
1991.PubMed/NCBI
|
|
10
|
Kojima S, Icho T, Hayashi M, Kajiwara Y,
Kitabatake K and Kubota K: Inhibitory effect of
5,6,7,8-tetrahydroneopterin on adriamycin-induced cardiotoxicity. J
Pharmacol Exp Ther. 266:1699–1704. 1993.PubMed/NCBI
|
|
11
|
Lee YS, Han JM, Kang T, Park YI, Kim HM
and Kim S: Antitumor activity of the novel human cytokine AIMP1 in
an in vivo tumor model. Mol Cells. 21:213–217. 2006.PubMed/NCBI
|
|
12
|
Sun L, Yang Q, Wang P, Liu D, Liang W, Lin
S and Yuan S: The influence of YS-1 on the Dll4-Notch1 signaling
pathway. Acta Biochim Biophys Sin (Shanghai). 46:56–64. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Park EJ, Kwon HK, Choi YM, Shin HJ and
Choi S: Doxorubicin induces cytotoxicity through upregulation of
pERK-dependent ATF3. PLoS One. 7:e449902012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Deschênes-Simard X, Kottakis F, Meloche S
and Ferbeyre G: ERKs in cancer: Friends or foes? Cancer Res.
74:412–419. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Collisson EA, Trejo CL, Silva JM, Gu S,
Korkola JE, Heiser LM, Charles RP, Rabinovich BA, Hann B, Dankort
D, et al: A central role for RAF→MEK→ERK signaling in the genesis
of pancreatic ductal adenocarcinoma. Cancer Discov. 2:685–693.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Kisucká J, Barancík M, Bohácová V and
Breier A: Reversal effect of specific inhibitors of
extracellular-signal regulated protein kinase pathway on
P-glycoprotein mediated vincristine resistance of L1210 cells. Gen
Physiol Biophys. 20:439–444. 2001.PubMed/NCBI
|
|
17
|
Lin JC, Chang SY, Hsieh DS, Lee CF and Yu
DS: Modulation of mitogen-activated protein kinase cascades by
differentiation-1 protein: Acquired drug resistance of hormone
independent prostate cancer cells. J Urol. 174:2022–2026. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Steelman LS, Abrams SL, Shelton JG,
Chappell WH, Bäsecke J, Stivala F, Donia M, Nicoletti F, Libra M,
Martelli AM, et al: Dominant roles of the Raf/MEK/ERK pathway in
cell cycle progression, prevention of apoptosis and sensitivity to
chemotherapeutic drugs. Cell Cycle. 9:1629–1638. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
McCubrey JA, Steelman LS, Chappell WH,
Abrams SL, Franklin RA, Montalto G, Cervello M, Libra M, Candido S,
Malaponte G, et al: Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascade
inhibitors: How mutations can result in therapy resistance and how
to overcome resistance. Oncotarget. 3:1068–1111. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
McCubrey JA, Steelman LS, Chappell WH,
Abrams SL, Wong EW, Chang F, Lehmann B, Terrian DM, Milella M,
Tafuri A, et al: Roles of the Raf/MEK/ERK pathway in cell growth,
malignant transformation and drug resistance. Biochim Biophys Acta.
1773:1263–1284. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
McCubrey JA, Steelman LS, Abrams SL, Lee
JT, Chang F, Bertrand FE, Navolanic PM, Terrian DM, Franklin RA,
D'Assoro AB, et al: Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT
pathways in malignant transformation and drug resistance. Adv
Enzyme Regul. 46:249–279. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Gebäck T, Schulz MM, Koumoutsakos P and
Detmar M: TScratch: A novel and simple software tool for automated
analysis of monolayer wound healing assays. Biotechniques.
46:265–274. 2009.PubMed/NCBI
|
|
23
|
Zhao R, Sun L, Lin S, Bai X, Yu B, Yuan S
and Zhang L: The saponin monomer of dwarf lilyturf tuber, DT-13,
inhibits angiogenesis under hypoxia and normoxia via
multi-targeting activity. Oncol Rep. 29:1379–1386. 2013.PubMed/NCBI
|
|
24
|
Kalimuthu S and Se-Kwon K: Cell survival
and apoptosis signaling as therapeutic target for cancer: Marine
bioactive compounds. Int J Mol Sci. 14:2334–2354. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Yoon EL, Yeon JE, Lee HJ, Suh SJ, Lee SJ,
Kang SH, Kang K, Yoo YJ, Kim JH, Yim HJ, et al: Systemic cytotoxic
chemotherapy of patients with advanced hepatocellular carcinoma in
the era of sorafenib nonavailability. J Clin Gastroenterol.
48:e22–e29. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Brown R, Curry E, Magnani L,
Wilhelm-Benartzi CS and Borley J: Poised epigenetic states and
acquired drug resistance in cancer. Nat Rev Cancer. 14:747–753.
2014. View
Article : Google Scholar : PubMed/NCBI
|
|
27
|
Kato T, Sato K, Kakinuma H and Matsuda Y:
Enhanced suppression of tumor growth by combination of angiogenesis
inhibitor O-(chloroacetyl-carbamoyl)fumagillol (TNP-470) and
cytotoxic agents in mice. Cancer Res. 54:5143–5147. 1994.PubMed/NCBI
|
|
28
|
Saijo N and Kenmotsu H: Recent development
of molecular-targeted drugs in lung cancer. Intern Med.
49:1923–1934. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Jia L, Zhang MH, Yuan SZ and Huang WG:
Antiangiogenic therapy for human pancreatic carcinoma xenografts in
nude mice. World J Gastroenterol. 11:447–450. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Shiota M, Eto M, Yokomizo A, Tada Y,
Takeuchi A, Masubuchi D, Inokuchi J, Tatsugami K, Kuroiwa K,
Uchiumi T, et al: Sorafenib with doxorubicin augments cytotoxicity
to renal cell cancer through PERK inhibition. Int J Oncol.
36:1521–1531. 2010.PubMed/NCBI
|
|
31
|
El-Kenawi AE and El-Remessy AB:
Angiogenesis inhibitors in cancer therapy: Mechanistic perspective
on classification and treatment rationales. Br J Pharmacol.
170:712–729. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Zhang L, Hannay JA, Liu J, Das P, Zhan M,
Nguyen T, Hicklin DJ, Yu D, Pollock RE and Lev D: Vascular
endothelial growth factor overexpression by soft tissue sarcoma
cells: Implications for tumor growth, metastasis, and
chemoresistance. Cancer Res. 66:8770–8778. 2006. View Article : Google Scholar : PubMed/NCBI
|
